Document is current
Any future updates will be listed below
-
Authors
Newman, Joseph A. https://orcid.org/0000-0003-4488-0516
Gavard, Angeline E.
Imprachim, Nergis https://orcid.org/0000-0001-5167-3203
Aitkenhead, Hazel
Sheppard, Hadley E.
te Poele, Robert https://orcid.org/0009-0001-3596-6572
Clarke, Paul A. https://orcid.org/0000-0001-9342-1290
Hossain, Mohammad Anwar https://orcid.org/0000-0001-8684-8755
Temme, Louisa
Oh, Hans J. https://orcid.org/0009-0007-2354-080X
Wells, Carrow I. https://orcid.org/0000-0003-4799-6792
Davis-Gilbert, Zachary W.
Workman, Paul https://orcid.org/0000-0003-1659-3034
Gileadi, Opher https://orcid.org/0000-0001-6886-898X
Drewry, David H. https://orcid.org/0000-0001-5973-5798
-
Funding
Funding for this research was provided by:
Bergmark Foundation
- License Information
-
More Information
Article History
Received: 9 May 2024
Accepted: 10 January 2025
First Online: 14 February 2025
Competing interests
: P.W. is or has been a consultant/scientific advisory board member for Alterome Therapeutics, Astex Pharmaceuticals, Black Diamond Therapeutics, Charm Therapeutics, CV6 Therapeutics, Cyclacel, EpiCombi AI, Merck KGaA, Nuevolution, Nextech Invest, and Vividion Therapeutics; received grant funding from Nuvectis and Vivan Therapeutics; is a Director of Derwentwater Associates, Storm Therapeutics, and the nonprofit Chemical Probes Portal; holds stock/options in Alterome Therapeutics, Black Diamond Therapeutics, Charm Therapeutics, Chroma Therapeutics, Nextech Invest, and Storm Therapeutics; and is a former employee of AstraZeneca. D.H.D. is on the scientific advisory board of the Chordoma Foundation. He previously served on the Board of Directors for the Chordoma Foundation. The remaining authors declare no competing interests.
